Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Zonisamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zonisamide SCHEMBL29358822 | 1.00 | LMNA (1.00) | LMNACA1CA2CA5ACA9 | |
| Zonisamide SCHEMBL4427407 | 1.00 | LMNA (1.00) | LMNACA1CA2CA5ACA9 | |
| Zonisamide SCHEMBL1816247 | 1.00 | LMNA (1.00) | LMNACA1CA2CA5ACA9 | |
| Zonisamide SCHEMBL688524 | 0.98 | LMNA (0.97) | LMNACA1CA2CA5ACA9 | |
| Zonisamide SCHEMBL689298 | 0.98 | LMNA (0.97) | LMNACA1CA2CA5ACA9 | |
| Zonisamide SCHEMBL1321446 | 0.98 | LMNA (0.97) | LMNACA1CA2CA5ACA9 | |
| Zonisamide SCHEMBL28757455 | 0.95 | LMNA (0.90) | LMNACA1CA2CA5ACA9 | |
| SCHEMBL3143718 | 0.84 | LMNA (0.73) | LMNACA1CA2CA5ACA9 | |
| SCHEMBL3239117 | 0.84 | LMNA (0.73) | LMNACA1CA2CA5ACA9 | |
| SCHEMBL1272549 | 0.84 | LMNA (0.73) | LMNACA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18699 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| US-12630599-B2 | CA2 compositions and methods for tunable regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| CN-122031677-A | Leptin receptor agonist antibodies for the treatment of metabolic dysfunction or hypoleptinemia | 瑞泽恩制药公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026102415-A1 | MICROBIAL BIOMARKERS OF CANINE IDIOPATHIC EPILEPSY | MARS, INCORPORATED (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260128144-A1 | Systems and Methods for Pharmacotherapeutic Intervention in Obesity Treatment Targeting Multiple Neurophysiological Mechanisms Using Patient Phenotyping Modeling | INTELLIHEALTH INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2000037616-A1 | COMPOUNDS, METHODS OF SCREENING AND METHODS OF TREATMENT FOR CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | CYTOSCAN SCIENCES L.L.C. (US) | 2000-06-29 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0396748-B1 | AGENT FOR TREATING ISCHEMIC BRAIN TROUBLE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | claimed |
| US-5248678-A | Administering adenosine receptor antagonist and a GABA antagonist | FRACTAL LABORATORIES, INC. (US) | 1993-09-28 | — | — | US | claimed |
| US-5128354-A | 3-sulfamoylmethyl-1,2-benzisooxazole | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | claimed |
| EP-0396748-A1 | AGENT FOR TREATING ISCHEMIC BRAIN TROUBLE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1990-11-14 | — | — | EP | claimed |
| US-4172896-A | ANTICONVULSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1979-10-30 | — | — | US | claimed |